16103 Federal Register / Vol. 85, No. 55 / Friday, March 20, 2020 / Notices 
Iowa, to form the White Family Control 
Group. 
B. Federal Reserve Bank of Kansas 
City (Dennis Denney, Assistant Vice 
President) 1 Memorial Drive, Kansas City, Missouri 64198–0001: 
1. Angel Reyes, Taos, New Mexico; 
Christopher Romero, San Cristobal, New Mexico; and Rebeca Romero Rainey, Arlington, Virginia; to be approved as 
members acting in concert with the Romero Family Control Group to acquire voting shares of Centinel Bank Shares, Inc. and thereby indirectly acquire voting shares of Centinel Bank of Taos, both of Taos, New Mexico. 
Board of Governors of the Federal Reserve 
System, March 17, 2020. 
Yao-Chin Chao, Assistant Secretary of the Board. 
[FR Doc. 2020–05916 Filed 3–19–20; 8:45 am] 
BILLING CODE 6210–01–P 
FEDERAL RETIREMENT THRIFT 
INVESTMENT BOARD 
Notice of March 23, 2020 FRTIB Board 
Member Meeting: Correction 
AGENCY : Federal Retirement Thrift 
Investment Board. 
ACTION : Notice, Correction. 
SUMMARY : 
Due to the COVID–19 pandemic, the 
March 23, 2020 FRTIB Board Member meeting will be conducted telephonically and not at the Agency’s 77 K St., Washington, DC location. Members of the public who are interested in the meeting can listen to the meeting by calling 1–877–446–3914 and using passcode 8249934. 
Issues caused by national higher-than- 
normal usage of phone lines may limit the number of individuals able to listen in on the meeting. Material relating to FRTIB Board meetings is available at frtib.gov. 
Contact Person for More Information: 
Kimberly Weaver, Director, Office of External Affairs, (202) 942–1640. 
Dated: March 17, 2020. 
Megan Grumbine, 
General Counsel, Federal Retirement Thrift 
Investment Board. 
[FR Doc. 2020–05892 Filed 3–19–20; 8:45 am] 
BILLING CODE 6760–01–P DEPARTMENT OF HEALTH AND 
HUMAN SERVICES 
Food and Drug Administration 
[Docket No. FDA–2019–D–5364] 
Submission of Plans for Cigarette 
Packages and Cigarette Advertisements; Guidance for Industry; Availability 
AGENCY : Food and Drug Administration, 
HHS. 
ACTION : Notice of availability. 
SUMMARY : The Food and Drug 
Administration (FDA) is announcing the availability of a final guidance for industry entitled ‘‘Submission of Plans for Cigarette Packages and Cigarette Advertisements.’’ This guidance is intended to assist those required to submit cigarette plans for cigarette packages and cigarette advertisements by providing content, timing, and other recommendations related to those submissions. 
DATES : The announcement of the 
guidance is published in the Federal Register on March 20, 2020. 
ADDRESSES : You may submit comments 
on any guidance at any time as follows: 
Electronic Submissions 
Submit electronic comments in the 
following way: 
•Federal eRulemaking Portal: 
https://www.regulations.gov. Follow the 
instructions for submitting comments. 
Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to 
the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. 
•If you want to submit a comment 
with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). 
Written/Paper Submissions 
Submit written/paper submissions as 
follows: •Mail/Hand Delivery/Courier (for 
written/paper submissions): Dockets 
Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. 
•For written/paper comments 
submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ‘‘Instructions.’’ 
Instructions: All submissions received 
must include the Docket No. FDA– 2019–D–5364 for ‘‘Submission of Plans for Cigarette Packages and Cigarette Advertisements.’’ Received comments will be placed in the docket and, except for those submitted as ‘‘Confidential Submissions,’’ publicly viewable at https://www.regulations.gov or at the 
Dockets Management Staff office between 9 a.m. and 4 p.m., Monday through Friday. 
•Confidential Submissions—To 
submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ‘‘THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.’’ The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit 
both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ‘‘confidential.’’ Any information marked as ‘‘confidential’’ will not be disclosed 
except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.govinfo.gov/content/pkg/FR-2015- 09-18/pdf/2015-23389.pdf. 
Docket: For access to the docket to 
read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the 
docket number, found in brackets in the heading of this document, into the ‘‘Search’’ box and follow the prompts and/or go to the Dockets Management 
VerDate Sep<11>2014 19:01 Mar 19, 2020 Jkt 250001 PO 00000 Frm 00057 Fmt 4703 Sfmt 4703 E:\FR\FM\20MRN1.SGM 20MRN1jbell on DSKJLSW7X2PROD with NOTICES16104 Federal Register / Vol. 85, No. 55 / Friday, March 20, 2020 / Notices 
Staff, 5630 Fishers Lane, Rm. 1061, 
Rockville, MD 20852. 
You may submit comments on any 
guidance at any time (see 21 CFR 10.115(g)(5)). 
Submit written requests for single 
copies of this guidance to the Center for Tobacco Products, Food and Drug Administration, Document Control Center, Bldg. 71, Rm. G335, 10903 New Hampshire Ave., Silver Spring, MD 20993–0002. Send one self-addressed adhesive label to assist that office in processing your request or include a fax number to which the guidance may be sent. See the 
SUPPLEMENTARY  
INFORMATION section for information on 
electronic access to the guidance. 
FOR FURTHER INFORMATION CONTACT : 
Lauren Belcher or Annette Marthaler, Center for Tobacco Products, Food and Drug Administration, 10903 New Hampshire Ave., Document Control Center, Bldg. 71, Rm. G335, 10903 New Hampshire Ave., Silver Spring, MD 20993–0002, 1–877–287–1373, email: AskCTPRegulations@fda.hhs.gov. 
SUPPLEMENTARY INFORMATION : 
I. Background 
FDA is announcing the availability of 
a guidance for industry entitled ‘‘Submission of Plans for Cigarette Packages and Cigarette Advertisements.’’ The Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act) (Pub. L. 111–31) was enacted on June 22, 2009, and granted FDA important new authority to regulate the manufacture, marketing, and distribution of tobacco products. The Tobacco Control Act also amended section 4 of the Federal Cigarette Labeling and Advertising Act (FCLAA) to direct FDA to issue regulations requiring each cigarette package and advertisement to bear a new textual warning label statement accompanied by color graphics depicting the negative health consequences of smoking (section 201 of the Tobacco Control Act). In enacting this legislation, Congress also provided that FDA may adjust the required warnings if FDA found that such a change would promote greater public understanding of the risks associated with the use of tobacco products (section 202 of the Tobacco Control Act). The Tobacco Control Act also modified the requirements of the FCLAA regarding the submission of cigarette plans for the random and equal display and distribution of required warnings on cigarette packages and quarterly rotation of required warnings in cigarette advertisements. It also requires that such cigarette plans be submitted to FDA for review and approval, rather than to the Federal Trade Commission. 
FDA issued a rule entitled ‘‘Tobacco 
Products; Required Warnings for Cigarette Packages and Advertisements’’ on March 18, 2020. The rule specifies the color graphics that must accompany the new textual warning label statements and establishes marketing requirements for cigarette packages and advertisements. The marketing requirements include, among other things, submission of a cigarette plan that provides for the random and equal display and distribution of the required warnings on cigarette packages and quarterly rotation of the required warnings in cigarette advertisements, as described under section 4 of FCLAA. 
This guidance provides 
recommendations related to preparing and submitting those cigarette plans. It discusses the regulatory requirements to submit cigarette plans as well as: 
•Who submits a cigarette plan; 
•the scope of a cigarette plan; 
•when to submit a cigarette plan; 
•what information should be 
submitted as part of a cigarette plan; 
•where to submit a cigarette plan; 
and 
•what approval of a cigarette plan 
means. 
FDA previously published a draft 
version of the guidance and sought public comment (84 FR 71957, December 30, 2019) (announcing the availability of the draft guidance). Among other things, comments express some concerns, such as about printing processes, as well as the difficulty of achieving random and equal display and distribution of required warnings. FDA has considered the comments it received, and included revisions in the final guidance that: (1) Discuss, per the final rule, that manufacturers may print different required warnings on front and rear panels of a cigarette package; (2) recognize that some level of deviation is appropriate given the language of the FCLAA; and (3) provide updated examples in an appendix to the guidance that demonstrate how random and equal display and distribution may be achieved with various printing methods, including those used by small manufacturers. 
II. Significance of Guidance 
FDA is issuing this guidance 
consistent with FDA’s good guidance 
practices regulation (21 CFR 10.115). The guidance represents the current thinking of FDA regarding the submission of cigarette plans for cigarette packages and advertisements. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative 
approach if it satisfies the requirements of the applicable statutes and regulations. 
III. Paperwork Reduction Act of 1995 
This guidance refers to collections of 
information described in FDA’s rule on 
‘‘Tobacco Products; Required Warnings for Cigarette Packages and Advertisements,’’ which this guidance is intended to interpret. These collections of information are subject to review by the Office of Management and 
Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501– 3521). The information collection provisions in the final rule have been submitted to OMB for review as required by section 3507(d) of the Paperwork Reduction Act of 1995. 
IV. Electronic Access 
Persons with access to the internet 
may obtain an electronic version of the 
guidance at either https://www.regulations.gov or https://
www.fda.gov/TobaccoProducts/ GuidanceComplianceRegulatoryInformation/default.htm. 
Dated: March 17, 2020. 
Lowell J. Schiller, 
Principal Associate Commissioner for Policy. 
[FR Doc. 2020–05936 Filed 3–19–20; 8:45 am] 
BILLING CODE 4164–01–P 
DEPARTMENT OF HEALTH AND 
HUMAN SERVICES 
Health Resources and Services 
Administration 
Meeting of the Advisory Council on 
Blood Stem Cell Transplantation 
AGENCY : Health Resources and Services 
Administration (HRSA), Department of Health and Human Services (HHS). 
ACTION : Notice. 
SUMMARY : In accordance with the 
Federal Advisory Committee Act, this notice announces that the Secretary’s Advisory Council on Blood Stem Cell Transplantation (ACBSCT) has scheduled a public meeting. Information about ACBSCT and the agenda for this meeting can be found on the ACBSCT website at https://bloodstemcell.hrsa.gov/about/advisory- council 
DATES : April 27, 2020, 8:00 a.m.–4:00 
p.m. Eastern Time (ET). 
ADDRESSES : This meeting will be held 
by webinar and conference call. The webinar link, conference call-in number, registration information, and meeting materials can be accessed 
VerDate Sep<11>2014 19:01 Mar 19, 2020 Jkt 250001 PO 00000 Frm 00058 Fmt 4703 Sfmt 4703 E:\FR\FM\20MRN1.SGM 20MRN1jbell on DSKJLSW7X2PROD with NOTICES